Search
Favezelimab
go.drugbank.com/drugs/DB16729InvestigationalFavezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A
Brimapitide
go.drugbank.com/drugs/DB15231InvestigationalBrimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Alendronic acid
go.drugbank.com/drugs/DB00630ApprovedInvestigationalIt functions by preventing resorption of bone[FDA Label][A959].
Delandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigationalDelandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics. … It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).
Canis lupus familiaris dander
go.drugbank.com/drugs/DB11018ApprovedCanis lupus familiaris dander is the dander of Canis lupus familiaris. Canis lupus familiaris dander is used in allergenic testing.
Mixtures: Animal Allergens, UF Dog Hair-Dander Canis sppBempedoic acid
go.drugbank.com/drugs/DB11936ApprovedInvestigational[L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020. … Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease.
Lorazepam
go.drugbank.com/drugs/DB00186ApprovedInvestigational[A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. … The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]
VidPrevtyn Beta
go.drugbank.com/drugs/DB16427ApprovedVidPrevtyn Beta is an adjuvanted, recombinant COVID-19 vaccine developed collaboratively by GlaxoSmithKline (GSK) and Sanofi Pasteur. … [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from
TrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082Approved[L64095] TrenibotulinumtoxinE was approved by Health Canada in June 2026[L64128] and by the European Commission on July 17, 2026, with the decision applying across all 30 European Economic Area countries … [L64095] It blocks neuromuscular transmission by cleaving SNAP-25, producing partial chemical denervation and a localized reduction in muscle activity.
Nusinersen
go.drugbank.com/drugs/DB13161ApprovedInvestigationalAn antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S.